Nonetheless, due to the drug resistance mechanisms and associated adverse events, most NSCLC patients treated with first- and second-generation EGFR-TKIs struggle to achieve progression-free survival (PFS) beyond 12 months, and this situation further exacerbate in patients with brain metastasis (Mok et al., 2009; Park et al., 2016; Westover et al., 2018; Zhao et al., 2019). This evidence concerns the gene EGFR and non-small cell lung carcinoma.